HomeHome
 
  • Homepage
  • Searching for patents

    Patent knowledge

    Access our patent databases and search tools.

    Go to overview 

    • Overview
    • Technical information
      • Overview
      • Espacenet - patent search
      • European Publication Server
      • Searching Asian documents: patent search and monitoring services
      • EP full-text search
      • Bibliographic coverage in Espacenet and OPS
      • Full-text coverage in Espacenet and OPS
    • Legal information
      • Overview
      • European Patent Register
      • European Patent Bulletin
      • European Case Law Identifier sitemap
      • Searching Asian documents
      • Third-party observations
    • Business information
      • Overview
      • PATSTAT
      • IPscore
      • Patent insight reports
    • Data
      • Overview
      • Linked open EP data
      • Bulk data sets
      • Web services
      • Coverage, codes and statistics
    • Helpful resources
      • Overview
      • First time here?
      • Asian patent information
      • Patent information centres
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge

    UP search

    Learn about the Unitary Patent in patent knowledge products and services

  • Applying for a patent

    Applying for a patent

    Practical information on filing and grant procedures.

    Go to overview 

    • Overview
    • European route
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
      • Appeals
      • Unitary Patent & Unified Patent Court
      • National validation
      • Request for extension/validation
    • International route (PCT)
      • Overview
      • Euro-PCT Guide – PCT procedure at the EPO
      • EPO decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
      • Training and events
    • National route
    • MyEPO services
      • Overview
      • Understand our services
      • Get access
      • File with us
      • Interact on your files
      • Online Filing & fee payment outages
      • Tutorials
    • Find a professional representative
    • Forms
      • Overview
      • Request for examination
    • Fees
      • Overview
      • European fees (EPC)
      • International fees (PCT)
      • Unitary Patent fees (UP)
      • Fee payment and refunds
      • Warning

    UP

    Unitary Patent

  • Law & practice

    Law & practice

    European patent law, the Official Journal and other legal texts.

    Go to overview 

    • Overview
    • Legal texts
      • Overview
      • European Patent Convention
      • Official Journal
      • Guidelines
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
      • Unitary patent system
      • National law relating to the UP
    • Court practices
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for professional representatives

    legal text

    Legal texts

  • News & events

    News & events

    Our latest news, podcasts and events, including the European Inventor Award.

    Go to overview 

     

    • Overview
    • News
    • Events
    • European Inventor Award
      • Overview
      • About the award
      • Categories and prizes
      • Meet the finalists
      • Nominations
      • Watch the 2022 ceremony
    • Press centre
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • Innovation and patenting in focus
      • Overview
      • Firefighting technologies
      • Green tech in focus
      • CodeFest on Green Plastics
      • Clean energy technologies
      • IP and youth
      • Research institutes
      • Women inventors
      • Fighting coronavirus
      • Lifestyle
      • Space and satellites
      • The future of medicine
      • Materials science
      • Mobile communications
      • Biotechnology
      • Patent classification
      • Digital technologies
      • The future of manufacturing
      • Books by EPO experts
    • "Talk innovation" podcast

    Podcast

    Listen to our podcast

  • Learning

    Learning

    The e-Academy – the point of access to your learning

    Go to overview 

    • Overview
    • European Patent Academy
      • Overview
      • Learning activities
      • Learning paths
    • Professional hub
      • Overview
      • EQE - European qualifying examination
      • EPAC - European patent administration certification
    • Learning resources by area of interest
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
    • Learning resources by area by profile
      • Overview
      • Business and IP managers
      • EQE candidates
      • Judges, lawyers and prosecutors
      • National offices and IP authorities
      • Patent attorneys and paralegals
      • Universities, research centres and technology transfer centres (TTOs)

    European Patent Academy

    Boost your IP knowledge with (e-)training from the European Patent Academy

  • About us

    About us

    Find out more about our work, values, history and vision

    Go to overview 

    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Overview
      • Official celebrations
      • Member states’ video statements
      • 50 Leading Tech Voices
      • Athens Marathon
      • Kids’ collaborative art competition
    • Legal foundations and member states
      • Overview
      • Legal foundations
      • Member states of the European Patent Organisation
      • Extension states
      • Validation states
    • Governance
      • Overview
      • Communiqués
      • Calendar
      • Documents and publications
      • Administrative Council
    • Principles & strategy
      • Overview
      • Our mission, vision, values and corporate policy
      • Public consultation on the EPO's Strategic Plan 2028
      • Towards a New Normal
    • Leadership & management
      • Overview
      • President António Campinos
      • Management Advisory Committee
    • Social responsibility
      • Overview
      • Environment and sustainability
      • Art collection
    • Services & activities
      • Overview
      • Our services & structure
      • Quality
      • Consulting our users
      • European and international co-operation
      • European Patent Academy
      • Chief Economist
      • Ombuds Office
      • Reporting wrongdoing
    • Observatory on Patents and Technology
      • Overview
      • About the Observatory
      • Our activities
      • Our topics
      • Our partners and networks
      • Digital library
      • Data desk
    • Procurement
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • About eTendering and electronic signatures
      • Procurement portal
      • Invoicing
      • General conditions
      • Archived tenders
    • Transparency portal
      • Overview
      • General
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
    • Statistics and trends
      • Overview
      • Statistics & Trends Centre
      • EPO Data Hub
      • Clarification on data sources
    • History
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s

    about us

    Patent Index 2022

 
en de fr
  • Language selection
  • English
  • Deutsch
  • Français
Main navigation
  • Homepage
  • New to patents
    • Go back
    • Overview
    • What's your big idea?
    • Are you ready?
    • What to expect
    • How to apply for a patent
    • Your business and patents
    • Is it patentable?
    • Are you first?
    • Why do we have patents?
    • Patent quiz
    • Unitary patent video
  • Searching for patents
    • Go back
    • Overview
    • Technical information
      • Go back
      • Overview
      • Espacenet - patent search
        • Go back
        • Overview
        • National patent office databases
        • Global Patent Index (GPI)
        • Release notes
      • European Publication Server
        • Go back
        • Overview
        • Cross-reference index for Euro-PCT applications
        • EP authority file
        • Help
      • Searching Asian documents
      • EP full-text search
      • Bibliographic coverage in Espacenet and OPS
      • Full-text coverage in Espacenet
    • Legal information
      • Go back
      • Overview
      • European Patent Register
        • Go back
        • Overview
        • Release notes archive
        • Register documentation
          • Go back
          • Overview
          • Deep link data coverage
          • Federated Register
          • Register events
      • European Patent Bulletin
        • Go back
        • Overview
        • Download Bulletin
        • EP Bulletin search
        • Help
      • European Case Law Identifier sitemap
      • Searching Asian documents
      • Third-party observations
    • Business information
      • Go back
      • Overview
      • PATSTAT
      • IPscore
        • Go back
        • Release notes
      • Patent insight reports
    • Data
      • Go back
      • Overview
      • Linked open EP data
      • Bulk data sets
        • Go back
        • Overview
        • Manuals
        • Sequence listings
        • National full-text data
        • European Patent Register data
        • EPO worldwide bibliographic data (DOCDB)
        • EP full-text data
        • EPO worldwide legal event data (INPADOC)
        • EP bibliographic data (EBD)
          • Go back
          • EBD files (weekly download) - free of charge
            • Go back
            • Secure EBD ST.36 files (weekly download) - for national patent offices only
        • Boards of Appeal decisions
        • EP full-text data for text analytics
      • Web services
        • Go back
        • Overview
        • Open Patent Services (OPS)
        • European Publication Server web service
      • Coverage, codes and statistics
        • Go back
        • Weekly updates
        • Updated regularly
    • Helpful resources
      • Go back
      • Overview
      • First time here? Patent information explained.
        • Go back
        • Overview
        • Basic definitions
        • Patent classification
          • Go back
          • Overview
          • Cooperative Patent Classification (CPC)
        • Patent families
          • Go back
          • Overview
          • DOCDB simple patent family
          • INPADOC extended patent family
        • Legal event data
          • Go back
          • Overview
          • INPADOC classification scheme
      • Asian patent information
        • Go back
        • Overview
        • China (CN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Chinese Taipei (TW)
          • Go back
          • Overview
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • India (IN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
        • Japan (JP)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Korea (KR)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Russian Federation (RU)
          • Go back
          • Overview
          • Facts and figures
          • Numbering system
          • Searching in databases
        • Useful links
      • Patent information centres (PATLIB)
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge
  • Applying for a patent
    • Go back
    • Overview
    • European route
      • Go back
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
        • Go back
        • Oral proceedings calendar
          • Go back
          • Calendar
          • Public access to appeal proceedings
          • Public access to opposition proceedings
          • Technical guidelines
      • Appeals
      • Unitary Patent & Unified Patent Court
        • Go back
        • Overview
        • Unitary Patent
          • Go back
          • Overview
          • Legal framework
          • Unitary Patent Guide
          • Main features
          • Applying for a Unitary Patent
          • Cost of a Unitary Patent
          • Translation and compensation
          • Start date
        • Unified Patent Court
      • National validation
      • Extension/validation request
    • International route
      • Go back
      • Overview
      • Euro-PCT Guide
      • Entry into the European phase
      • Decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
        • Go back
        • Patent Prosecution Highway (PPH) programme outline
      • Training and events
    • National route
    • MyEPO services
      • Go back
      • Overview
      • Understand our services
        • Go back
        • Overview
        • Online Filing 2.0 pilot
        • MyEPO Portfolio - pilot phase
        • Online Filing 2.0 pilot continuation
        • Exchange data with us using an API
      • Get access
        • Go back
        • Overview
        • Installation and activation
      • File with us
        • Go back
        • Overview
        • What if our online filing services are down?
        • Release notes
      • Interact on your files
      • Online Filing & fee payment outages
      • Tutorials
    • Fees
      • Go back
      • Overview
      • European fees (EPC)
        • Go back
        • Overview
        • Decisions and notices
      • International fees (PCT)
        • Go back
        • Reduction in fees
        • Fees for international applications
        • Decisions and notices
        • Overview
      • Unitary Patent fees (UP)
        • Go back
        • Overview
        • Decisions and notices
      • Fee payment and refunds
        • Go back
        • Overview
        • Payment methods
        • Getting started
        • FAQs and other documentation
        • Technical information for batch payments
        • Decisions and notices
        • Release notes
      • Warning
    • Forms
      • Go back
      • Request for examination
    • Find a professional representative
  • Law & practice
    • Go back
    • Overview
    • Legal texts
      • Go back
      • Overview
      • European Patent Convention
        • Go back
        • Overview
        • Archive
          • Go back
          • Overview
          • Documentation on the EPC revision 2000
            • Go back
            • Overview
            • Diplomatic Conference for the revision of the EPC
            • Travaux préparatoires
            • New text
            • Transitional provisions
            • Implementing regulations to the EPC 2000
            • Rules relating to Fees
            • Ratifications and accessions
          • Travaux Préparatoires EPC 1973
      • Official Journal
      • Guidelines
        • Go back
        • Overview
        • EPC Guidelines
        • PCT-EPO Guidelines
        • Guidelines revision cycle
        • Consultation results
        • Summary of user responses
        • Archive
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
        • Go back
        • Overview
        • Archive
      • Unitary Patent system
      • National measures relating to the Unitary Patent 
    • Court practices
      • Go back
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Go back
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Go back
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for professional representatives
  • News & events
    • Go back
    • Overview
    • News
    • Events
    • European Inventor Award
      • Go back
      • Overview
      • About the award
      • Categories and prizes
      • Meet the finalists
      • Nominations
      • Watch the 2023 ceremony
      • European Inventor Network
        • Go back
        • Activities granted in 2023
    • Press centre
      • Go back
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
        • Go back
        • Overview
        • European Patent Office
        • Q&A on patents related to coronavirus
        • Q&A on plant patents
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • In focus
      • Go back
      • Overview
      • Firefighting technologies
        • Go back
        • Overview
        • Detection and prevention of fires
        • Fire extinguishing
        • Protective equipment
        • Post-fire restoration
      • Green tech in focus
        • Go back
        • Overview
        • About green tech
        • Renewable energies
        • Energy transition technologies
        • Building a greener future
      • CodeFest on Green Plastics
      • Clean energy technologies
        • Go back
        • Overview
        • Renewable energy
        • Carbon-intensive industries
        • Energy storage and other enabling technologies
      • IP and youth
      • Research institutes
      • Women inventors
      • Fighting coronavirus
        • Go back
        • Overview
        • Vaccines and therapeutics
          • Go back
          • Overview
          • Vaccines
          • Overview of candidate therapies for COVID-19
          • Candidate antiviral and symptomatic therapeutics
          • Nucleic acids and antibodies to fight coronavirus
        • Diagnostics and analytics
          • Go back
          • Overview
          • Protein and nucleic acid assays
          • Analytical protocols
        • Informatics
          • Go back
          • Overview
          • Bioinformatics
          • Healthcare informatics
        • Technologies for the new normal
          • Go back
          • Overview
          • Devices, materials and equipment
          • Procedures, actions and activities
          • Digital technologies
        • Inventors against coronavirus
      • Lifestyle
      • Space and satellites
        • Go back
        • Overview
        • Patents and space technologies
      • Healthcare
        • Go back
        • Overview
        • Medical technologies and cancer
        • Personalised medicine
      • Materials science
        • Go back
        • Overview
        • Nanotechnology
      • Mobile communications
      • Biotechnology
        • Go back
        • Overview
        • Red, white or green
        • The role of the EPO
        • What is patentable?
        • Biotech inventors
      • Classification
        • Go back
        • Overview
        • Nanotechnology
        • Climate change mitigation technologies
          • Go back
          • Overview
          • External partners
          • Updates on Y02 and Y04S
      • Digital technologies
        • Go back
        • Overview
        • About ICT
        • Hardware and software
        • Patents and standards
        • Artificial intelligence
        • Fourth Industrial Revolution
      • Additive manufacturing
        • Go back
        • Overview
        • About AM
        • AM innovation
      • Books by EPO experts
    • Podcast
  • Learning
    • Go back
    • Overview
    • European Patent Academy
      • Go back
      • Overview
      • Learning activities
      • Learning Paths
    • Professional hub
      • Go back
      • Overview
      • EPAC - European patent administration certification
      • EQE - European Qualifying Examination
        • Go back
        • Overview
        • Archive
        • Candidates successful in the European qualifying examination
        • Compendium
          • Go back
          • Overview
          • Pre-examination
          • Paper A
          • Paper B
          • Paper C
          • Paper D
    • Learning resources by area of interest
      • Go back
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
        • Go back
        • Overview
        • Patent enforcement in Europe
        • Patent litigation in Europe
    • Learning resources by profile
      • Go back
      • Overview
      • Business and IP managers
        • Go back
        • Overview
        • Innovation case studies
          • Go back
          • Overview
          • SME case studies
          • Technology transfer case studies
          • High-growth technology case studies
        • Inventors' handbook
          • Go back
          • Overview
          • Introduction
          • Disclosure and confidentiality
          • Novelty and prior art
            • Go back
            • Overview
            • Is the idea ‘obvious’?
            • Prior art searching
            • Professional patent searching
            • Simple Espacenet searching
            • What is prior art?
            • Why is novelty important?
          • Competition and market potential
            • Go back
            • Overview
            • Research guidelines
          • Assessing the risk ahead
            • Go back
            • Overview
            • Exploitation routes
            • Significant commercial potential
            • Significant novelty
            • What about you?
            • What if your idea is not novel but does have commercial potential?
          • Proving the invention
            • Go back
            • Overview
            • Help with design or redesign
            • Prototype strategy
          • Protecting your idea
            • Go back
            • Overview
            • Forms of IPR
            • Patenting strategy
            • The patenting process
          • Building a team and seeking funding
            • Go back
            • Overview
            • Building a team
            • Sources of funding
            • Sources of help for invention
          • Business planning
            • Go back
            • Overview
            • Constructing a business plan
            • Keep it short!
          • Finding and approaching companies
            • Go back
            • Overview
            • First contact
            • Meetings
          • Dealing with companies
            • Go back
            • Overview
            • Advance or guaranteed payment
            • Companies and your prototype
            • Full agreement – and beyond
            • Negotiating a licensing agreement
            • Reaching agreement
            • Royalties
        • Best of search matters
          • Go back
          • Overview
          • Tools and databases
          • EPO procedures and initiatives
          • Search strategies
          • Challenges and specific topics
        • Support for high-growth technology businesses
          • Go back
          • Overview
          • For IP professionals
          • For business decision-makers
          • For stakeholders of the innovation ecosystem
      • EQE Candidates
        • Go back
        • Overview
        • Coffee-break questions
        • Daily D questions
        • European qualifying examination - Guide for preparation
      • Judges, lawyers and prosecutors
        • Go back
        • Overview
        • Compulsory licensing in Europe
        • The jurisdiction of European courts in patent disputes
      • National offices and IP authorities
        • Go back
        • Overview
        • Learning material for examiners of national officers
        • Learning material for formalities officers and paralegals
      • Patent attorneys and paralegals
      • Universities, research centres and TTOs
        • Go back
        • Overview
        • Modular IP Education Framework (MIPEF)
        • Pan-European Seal Young Professionals Programme
          • Go back
          • Overview
          • For students
          • For universities
            • Go back
            • Overview
            • IP education resources
            • University memberships
          • Our young professionals
          • Professional development plan
        • Academic Research Programme
          • Go back
          • Overview
          • Completed research projects
          • Current research projects
        • IP Teaching Kit
          • Go back
          • Overview
          • Download modules
        • Intellectual property course design manual
  • About us
    • Go back
    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Go back
      • Official celebrations
      • Overview
      • Member states’ video statements
        • Go back
        • Albania
        • Austria
        • Belgium
        • Bulgaria
        • Croatia
        • Cyprus
        • Czech Republic
        • Denmark
        • Estonia
        • Finland
        • France
        • Germany
        • Greece
        • Hungary
        • Iceland
        • Ireland
        • Italy
        • Latvia
        • Liechtenstein
        • Lithuania
        • Luxembourg
        • Malta
        • Monaco
        • Montenegro
        • Netherlands
        • North Macedonia
        • Norway
        • Poland
        • Portugal
        • Romania
        • San Marino
        • Serbia
        • Slovakia
        • Slovenia
        • Spain
        • Sweden
        • Switzerland
        • Türkiye
        • United Kingdom
      • 50 Leading Tech Voices
      • Athens Marathon
      • Kids’ collaborative art competition
    • Legal foundations and member states
      • Go back
      • Overview
      • Legal foundations
      • Member states
        • Go back
        • Overview
        • Member states by date of accession
      • Extension states
      • Validation states
    • Governance
      • Go back
      • Overview
      • Communiqués
        • Go back
        • Overview
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
        • 2017
        • 2016
        • 2015
        • 2014
        • 2013
      • Calendar
      • Documents and publications
        • Go back
        • Overview
        • Select Committee documents
      • Administrative Council
        • Go back
        • Overview
        • Composition
        • Representatives
        • Rules of Procedure
        • Board of Auditors
        • Secretariat
        • Council bodies
    • Principles & strategy
      • Go back
      • Overview
      • Mission, vision, values & corporate policy
      • Strategic Plan 2028
      • Towards a New Normal
      • Data protection & privacy notice
    • Leadership & management
      • Go back
      • Overview
      • About the President
      • Management Advisory Committee
    • Procurement
      • Go back
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • About eTendering
      • Procurement portal
        • Go back
        • Overview
        • e-Signing contracts
      • Invoicing
      • General conditions
      • Archived tenders
    • Services & activities
      • Go back
      • Overview
      • Our services & structure
      • Quality
        • Go back
        • Overview
        • Foundations
          • Go back
          • Overview
          • European Patent Convention
          • Guidelines for examination
          • Our staff
        • Enabling quality
          • Go back
          • Overview
          • Prior art
          • Classification
          • Tools
          • Processes
        • Products & services
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
          • Continuous improvement
        • Quality through networking
          • Go back
          • Overview
          • User engagement
          • Co-operation
          • User satisfaction survey
          • Stakeholder Quality Assurance Panels
        • Patent Quality Charter
        • Statistics
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
      • Consulting our users
        • Go back
        • Overview
        • Standing Advisory Committee before the EPO (SACEPO)
          • Go back
          • Overview
          • Objectives
          • SACEPO and its working parties
          • Meetings
          • Single Access Portal – SACEPO Area
        • Surveys
          • Go back
          • Overview
          • Search services
          • Examination services, final actions and publication
          • Opposition services
          • Patent filings
            • Go back
            • Overview
            • Detailed methodology
            • Archive
          • Online Services
          • Patent information
            • Go back
            • Overview
            • Innovation process survey
          • Customer services
          • Filing services
          • Website
          • Survey on electronic invoicing
          • Companies innovating in clean and sustainable technologies
      • Our user service charter
      • European and international co-operation
        • Go back
        • Overview
        • Co-operation with member states
          • Go back
          • Overview
        • Bilateral co-operation with non-member states
          • Go back
          • Overview
          • Validation system
          • Reinforced Partnership programme
        • Multilateral international co-operation with IP offices and organisations
        • Co-operation with international organisations outside the IP system
      • European Patent Academy
        • Go back
        • Overview
        • Partners
      • Chief Economist
        • Go back
        • Overview
        • Economic studies
      • Ombuds Office
      • Reporting wrongdoing
    • Statistics and trends
      • Go back
      • Overview
      • Statistics & Trends Centre
      • EPO Data Hub
      • Clarification on data sources
    • Social responsibility
      • Go back
      • Overview
      • Environment
      • Art collection
        • Go back
        • Overview
        • The collection
        • Let's talk about art
        • Artists
        • Media library
        • What's on
        • Publications
        • Contact
        • Culture Space A&T 5-10
          • Go back
          • Catalyst lab & Deep vision
            • Go back
            • aqua_forensic
            • LIMINAL
            • MaterialLab
            • Perfect Sleep
            • Proof of Work
            • TerraPort
            • Unfinished Sculpture - Captives #1
            • Deep vision – immersive exhibition
          • The European Patent Journey
          • Sustaining life. Art in the climate emergency
          • Next generation statements
          • Open storage
          • Cosmic bar
        • Lange Nacht 2023
    • History
      • Go back
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s
    • Transparency portal
      • Go back
      • Overview
      • General
        • Go back
        • Overview
        • Annual Review 2022
          • Go back
          • Overview
          • Foreword
          • Executive summary
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
    • Observatory on Patents and Technology
      • Go back
      • Overview
      • About the Observatory
      • Our activities
      • Our topics
      • Our partners and networks
      • Digital library
      • Data desk
  • Boards of Appeal
    • Go back
    • Overview
    • Decisions of the Boards of Appeal
      • Go back
      • Overview
      • Recent decisions
      • Selected decisions
    • Procedure
    • Annual reports
      • Go back
      • Overview
    • Organisation
      • Go back
      • Overview
      • President of the Boards of Appeal
      • Enlarged Board of Appeal
        • Go back
        • Overview
        • Pending referrals (Art. 112 EPC)
        • Decisions sorted by number (Art. 112 EPC)
        • Pending petitions for review (Art. 112a EPC)
        • Decisions on petitions for review (Art. 112a EPC)
      • Technical Boards of Appeal
      • Legal Board of Appeal
      • Disciplinary Board of Appeal
      • Presidium
        • Go back
        • Overview
        • Composition of the Presidium
          • Go back
          • Overview
          • Archive
    • Code of Conduct
    • Business distribution scheme
      • Go back
      • Overview
      • Technical boards of appeal by IPC in 2023
      • Archive
    • Annual list of cases
    • Communications
    • Publications
    • Case Law of the Boards of Appeal
      • Go back
      • Overview
      • Archive
    • Case Law from the Contracting States to the EPC
    • Oral proceedings
  • Service & support
    • Go back
    • Overview
    • Website updates
    • Availability of online services
      • Go back
      • Overview
    • FAQ
      • Go back
      • Overview
    • Publications
    • Ordering
      • Go back
      • Overview
      • Terms and conditions
        • Go back
        • Overview
        • Patent information products
        • Bulk data sets
        • Open Patent Services (OPS)
        • Fair use charter
    • Procedural communications
    • Useful links
      • Go back
      • Overview
      • Patent offices of member states
      • Other patent offices
      • Legal resources
      • Directories of patent attorneys
      • Patent databases, registers and gazettes
      • Disclaimer
    • Contact us
      • Go back
      • Overview
      • Filing options
      • Locations
      • Specific contact
    • Subscription centre
      • Go back
      • Overview
      • Subscribe
      • Change preferences
      • Unsubscribe
    • Official holidays
    • Forums
    • Glossary
    • RSS feeds
1995
  1. Home
  2. Legal texts
  3. Official Journal
  4. 1995
  5. 3 - March
  6. Pages 113-125
Print
Facebook Twitter Linkedin Email
3 - March

Overview

Pages 113-125

Download PDF 
Citation: OJ EPO 1995, 113
Online publication date: 31.3.1995
BOARDS OF APPEAL
Decisions of the Technical Boards of Appeal

Decision of Technical Board of Appeal 3.3.2 dated 11 January 1994 - T 820/92 - 3.3.2

(Official text)

Composition of the board:

Chairman:

U. M. Kinkeldey

Members:

L. Galligani

 

S. C. Perryman

Applicant: The General Hospital Corporation

Headword: Contraceptive method/THE GENERAL HOSPITAL

Article: 52(4), 57 EPC

Keyword: "Patentability of a contraceptive method involving a concurrent therapeutic step (no)" - "Presence of one step prohibited under Article 52(4) EPC prevents method being allowable"

Headnote

In the case of a method involving administration of two or more substances (here: an LHRH contraceptive composition and oestrogenic and/or progestational steroids) the question for the purposes of Article 52(4) EPC is not whether the main or even the only reason for carrying out the whole of the claimed method is non-therapeutic. Rather a method claim falls under the prohibition of Article 52(4) EPC already if the purpose of the administration of one of the substances is a treatment by therapy, and the administration of this substance is a feature of the claim (see point 5.9 of the reasons).

Summary of facts and submissions

I. European patent application No. 87 902 913.0 filed as an international patent application and published under No. WO 87/05514 was refused by the examining division.

The decision was taken on the basis of claims 1 to 13 filed by letter dated 26 April 1991.

II. The ground for refusal was that claims 8 to 13 did not comply with the requirements of Article 57 EPC.

The decision was essentially based on the following reasons:

(a) Claims 8 to 13 related to a method for preventing pregnancy in female mammals, inter alia human females (see claim 9). The claims encompassed the personal and private use of the contraceptive (see claim 10: oral intake).

(b) Notwithstanding the lack of an explicit exclusion from patentability in the European Patent Convention (EPC) and the absence of case law thereon, it was current practice of the European Patent Office (EPO) not to allow claims to methods of contraception of a human female where such methods involved the personal and private use of a substance. This was because the said use did not fall within the definition of industrial application set forth in Article 57 EPC.

(c) Decision T 144/83, OJ EPO 1986, 301, referred to by the applicant, was not concerned with a method of contraception, but with a cosmetic method. Although the said decision implied that the private oral administration of non-therapeutic substances was acceptable under Article 57 EPC, the highly personal and confidential nature of contraception clearly distinguished the methods for preventing pregnancy from cosmetic methods and from the administration of food.

III. The appellant lodged an appeal against this decision and paid the appeal fee. First and second auxiliary requests were filed by the appellant with the statement of grounds of appeal.

IV. In an official communication pursuant to Article 110(2) EPC the board indicated two further questions to be taken into consideration, namely, (i) whether the combination of a contraceptive method with a therapeutic method was excluded from patentability under Article 52(4) EPC and (ii) whether any of the requests on file met the requirements of Article 84 EPC.

V. During oral proceedings which took place on 11 January 1994 a new main request and a first and second auxiliary request were filed in one version for all states.

Claim 1 of the main request reads as follows:

"A delivery system for preventing pregnancy in a female mammal, comprising:

(1) a first delivery system, for administration to said mammal during the follicular phase of the menstrual cycle, comprising a contraceptive effective amount of an LHRH composition and a physiologically effective amount of an estrogenic steroid; and,

(2) a second delivery system, for administration to said mammal during the luteal phase of the menstrual cycle, comprising a contraceptive effective amount of an LHRH composition, a physiologically effective amount of an estrogenic steroid and a physiologically effective amount of progestational steroid."

Claims 2 to 7 relate to specific embodiments of the delivery system according to claim 1.

Claim 8 of the main request reads as follows:

"A method for preventing pregnancy in a female mammal, comprising:

(a) administering via a delivery system a contraceptive effective amount of an LHRH composition and a physiologically effective amount of an estrogenic steroid to said female during the follicular phase of the menstrual cycle, beginning at the onset of normal menses in said female; and,

(b) replacing first said delivery system at the end of said follicular phase with a second delivery system, wherein said second delivery system administers a contraceptive effective amount of an LHRH composition, a physiologically effective amount of an estrogenic steroid and a physiologically effective amount of progestational steroid to said female during the luteal phase of the menstrual cycle, until the beginning of the normal menses in said female."

Claims 9 to 13 relate to specific embodiments of the method according to claim 8.

The first auxiliary request differs from the main request in that claim 8 reads as follows:

"The use of an LHRH composition, an estrogenic steroid and a progestational steroid in the preparation of an agent for preventing pregnancy in a female mammal, the agent comprising:

(1) a first delivery system, for administration to said mammal during the follicular phase of the menstrual cycle, comprising a contraceptive effective amount of an LHRH composition and a physiologically effective amount of an estrogenic steroid; and,

(2) a second delivery system, for administration to said mammal during the luteal phase of the menstrual cycle, comprising a contraceptive effective amount of an LHRH composition, a physiologically effective amount of an estrogenic steroid and a physiologically effective amount of progestational steroid."

Dependent claims 9 to 14 therein relate to specific embodiments of the said use.

The second auxiliary request differs from the main request in that claims 8 to 13 are deleted.

The appellant's arguments with respect to the objection raised by the board under Article 52(4) EPC are essentially as follows:

(a) While the oestrogenic and progestational steroids were not added in the delivery system of the present application as contraceptive, but to correct any biological functions adversely affected by the LHRH, the overall effect of the claimed delivery system was a contraceptive effect. Therapy was not the subject-matter of the claims. The method claims, in particular, were directed to the prevention of pregnancy and not to a therapeutic application. The presence in the delivery system of physiologically effective amounts of oestrogenic and progestational steroids was to be regarded merely as an "advantage" of the system by which any health problems caused by the main contraceptive ingredient (LHRH composition) were alleviated.

(b) Reference was made to the case law of the United Kingdom, France and Germany to show that:

(i) pregnancy was not a disease;

(ii) contraception was not regarded as a form of disease therapy;

(iii) contraception was therefore not a method of medical treatment by virtue of national case law or medical definition.

Thus, since the present method claims were directed only to the prevention of pregnancy, no exclusion under Article 52(4) EPC should apply.

(c) According to the established European case law, any exceptions to patentability should be construed narrowly (see, for example, T 320/87OJ EPO 1990, 71, point 6, and T 19/90OJ EPO 1990, 476, point 4.5).

In cases T 144/83 (loc.cit.) and T 36/83 (OJ EPO 1986, 295) where no clear distinction was possible between the therapeutic and the cosmetic effect the board did not allow this to work to the disadvantage of the applicant and allowed the method for cosmetic treatment.

In decision T 290/86 (OJ EPO 1992, 414) the board emphasised the importance of the wording of a claim for deciding whether or not a claimed invention should be excluded from patentability under Article 52(4) EPC. In the light of the latter decision, the exclusion from patentability under Article 52(4) EPC would be justified only if the present method claims were directed to "the use of steroids for preventing or alleviating the side effects of LHRH". However, the present claims were directed to a method for preventing pregnancy; thus, they should be allowed.

(d) According to decision T 208/84 (OJ EPO 1987, 14), even if the idea underlying an invention might be considered to reside in a mathematical method (which was per se excluded from patentability under Article 52(2)(a) EPC), a claim directed to a technical process in which the method was used did not seek protection for the mathematical method as such and, therefore, was not excluded from patentability. In the light of said decision, no exclusion under Article 52(4) EPC should apply in the present case because the claimed method of contraception did not seek protection for the therapeutic effect of the added oestrogenic and progestational steroids.

The appellant also submitted other arguments relating to the grounds of rejection by the examining division.

VI. The appellant requested that the decision under appeal be set aside and that a patent be granted on the basis of the main request, or the first auxiliary request or second auxiliary request, as submitted during the oral proceedings.

Reasons for the decision

1. The appeal is admissible.

2. Formal admissibility of the new sets of claims (Article 123(2) EPC)

Claim 1 of each request has been amended to make clear that the delivery systems actually comprise an LHRH composition and one or more steroids, thus overcoming the clarity objection raised in the first official communication by the board. This amendment finds its basis in the original application documents (see, for example, page 12, lines 11 to 18, and page 4, second paragraph).

Moreover, in claim 1 of all requests and in claim 8 of the main and first auxiliary request the effective amount of the oestrogenic and progestational steroid has been qualified by the introduction of the adverb "physiologically". This amendment finds a basis in the original application documents (see, for example, page 10, lines 21 to 22, and page 11, lines 4 to 5).

Thus, no objection under Article 123(2) EPC arises.

3. Clarity (Article 84 EPC)

The claimed subject-matter is adequately defined to meet the requirements of Article 84 EPC. The adopted functional language ("contraceptive effective amount" and "physiologically effective amount") is allowable and in line with the case law (see in particular T 68/85, OJ EPO 1987, 228).

4. Patentability of the product claims 1 to 7 of all requests

During substantive examination the examining division acknowledged the patentability under Article 52(1) EPC of the delivery system according to claims 1 to 7 (see appealed decision, point 8). Also in the board's view, none of the available prior art documents, alone or in combination, discloses or suggests the claimed delivery system. This is, therefore, considered patentable under the provisions of Articles 54 and 56 EPC.

No other objections to the patentability of these claims were seen.

5. Main request: the method claims 8 to 13

5.1 Claim 8 is directed to a method for preventing pregnancy in a female mammal. The contraceptive effect on the female mammal is ensured through the administration of an LHRH composition.

The administration of the large doses of LHRH compositions which are necessary to block ovulation in the female produces a reversible and complete biochemical castration at pituitary level which results in a total suppression of gonadotropin and ovarian steroids secretions (estradiol and progesterone) (see present description pages 2 to 3). This pituitary quiescence leads to the side effects of oestrogen deficiency, including hot flashes, vaginal dryness and, most ominously, osteopenia and osteoporosis (see description, page 3, lines 23 to 29; page 10, lines 26 to 28, and page 11, second paragraph).

The oestrogenic and progestational steroids are administered according to the claimed method not to maintain or reinforce the contraceptive effect of LHRH, but only to "mimic the physiological secretion of steroids in the menstrual cycle" (see page 5, lines 5 to 7 of the description) and thereby to counteract the above side effects. In fact, "physiologically" effective amounts of the said steroids are administered in order to compensate for the total suppression of their secretion caused by the LHRH composition.

5.2 It is established case law that a prophylactic treatment, aimed at maintaining health by preventing ill effects that would otherwise arise, amounts to a method for treatment by therapy as referred to in Article 52(4) EPC, and that therapy is not limited to treatments which restore health by curing diseases which have already arisen (T 144/83, loc.cit.; T 81/84, OJ EPO 1988, 207; T 19/86, OJ EPO 1989, 25; G 5/83, OJ EPO 1985, 64).

In the present case while the treatment of the female mammal with the LHRH composition is carried out to produce the desired contraceptive effect, the concurrent treatment with the oestrogenic and progestational steroids is carried out not to produce any contraceptive effect but as a prophylactic treatment which avoids the ill consequences which would otherwise occur as a result of the use of the LHRH composition. This latter step is a treatment by therapy within the meaning of Article 52(4) EPC.

5.3 The appellant sought to avoid this conclusion by arguing that the method as a whole is a contraceptive method and that this avoids the prohibition of Article 52(4) EPC applying to the claim. This argument is based on a misconception of the nature of the prohibition of Article 52(4) EPC. By providing that methods for treatment of the human or animal body by surgery or therapy and diagnostic methods practised on the human or animal body shall not be regarded as inventions which are susceptible of industrial application, the first sentence of Article 52(4) EPC creates an exclusion from patentability that has been consistently interpreted by the EPO boards of appeal as meaning that such a method cannot be the subject-matter or part of the subject-matter covered by a claim.

5.4 The parallel drawn by the appellant with case T 208/84 (VICOM) (loc.cit.) is not considered pertinent. Article 52(2) EPC provides that certain activities of an abstract and intellectual character shall not be regarded as inventions, but Article 52(3) EPC provides that this exclusion applies only to the activities as such. This has been interpreted as meaning only that a claim directed to such activities per se is not allowable but that a claim is allowable where the interaction of such an activity with something else can be regarded as an invention. This contrasts with the position under Article 52(4) EPC which prevents the methods specified from being patented, even though otherwise they might be considered as an invention susceptible of industrial application as required by Article 52(1) EPC. It is to be noted that no provision similar to Article 52(3) EPC limits the exclusion of Article 52(4) EPC.

5.5 The decided cases show that in considering whether a request for a particular set of claims is allowable under Article 52(4) EPC, the critical question is whether there is any disclosure of a method none of whose steps fall under the prohibition of Article 52(4) EPC, ie none of whose steps are either a method for the treatment of the human or animal by therapy or surgery, or a diagnostic method practised on the human or animal body. The question is not merely one of having a suitably worded claim, but whether on the disclosure of the case such a method claim is allowable at all.

5.6 No method claim was considered allowable in case T 290/86 (loc.cit.) because the disclosed method of eliminating plaque inevitably had the therapeutic effect of prevention of caries and periodontal disease, and so fell under the prohibition of Article 52(4) EPC, irrespective of the fact that removal of plaque could also have the cosmetic effect of improving the appearance of the teeth.

Nor was a method claim considered allowable in case T 780/89 (OJ EPO 1993, 440) where the appellant argued that immunostimulation was used to improve meat production and not as a therapeutic treatment. However the board considered that this did not alter the legal position (see reasons, point 7) since even if more meat was produced because fewer animals became sick or died, the method for which patent protection was claimed remained a therapeutic treatment.

In case T 116/85 (OJ EPO 1989, 13) the board considered that the particular use disclosed of a pesticidal composition to treat pigs to remove ectoparasites (mange mites) amounted to a therapeutic treatment, so that claims to this use fell under the prohibition of Article 52(4) EPC even though in general agricultural uses were patentable. It did not accept that merely because such a method carried out by a farmer could be considered industrial this would make the method lose its character of being treatment by therapy.

In each of these three cases the appellant had failed to satisfy the board that the method claims were not directed to a use prohibited by Article 52(4) EPC.

5.7 In case T 144/83 (loc.cit.), particularly relied on by the appellant, the board considered that the claimed use of an appetite suppressant was unrelated to the therapy of the human or animal body, and that the claims were formulated to clearly relate to a non-therapeutic use. The decision thus turns on the facts found by the board in that particular case. It is also said there that exclusions from patentability such as Article 52(4) EPC must be construed narrowly and should not apply to treatments which are not therapeutic in character, and that the difficulty in distinguishing between a therapeutic and a cosmetic effect should not be allowed to work to the disadvantage of the applicant who, according to the wording of his claims, seeks patent protection for cosmetic treatment but not for the therapeutic treatment as such. This must be seen in the context of the view of the board that a non-therapeutic use of this particular treatment clearly existed. The case is no authority for the propositions that if there is any doubt as to whether the prohibition of Article 52(4) EPC applies it must be resolved in the applicant's favour, or that something described as a cosmetic treatment can ipso facto be considered as non-therapeutic.

In T 36/83 (loc.cit.) the board found that there was described both a novel non-medical use and a novel medical use of thenoyl peroxide, particularly as a comedolytic, and accordingly allowed both a claim to a cosmetic use, and a claim to the compound for use in a method of therapeutic treatment for the human or animal body under the provisions of Article 54(5) EPC. In reaching this conclusion the board treated the use of the word "cosmetic" in the context of this application as sufficient to exclude therapeutic uses, without the need for a specific disclaimer of such uses.

In each of these cases the board had thus satisfied itself that no method of treatment by therapy was covered by the claims it allowed.

5.8 In case T 182/90 of 30 July 1993 (OJ EPO 1994, 641), method claims were allowed even though one step of the method included a surgical step on a living animal. But they were allowed (see reasons, point 2.5.2) on the basis that the method used in that case consciously ended in the laboratory animal's death, and this prevented the surgical step from being considered a prohibited treatment by surgery. The board stated in reasons, point 2.5.1, that normally the presence of a surgical step in a multi-step method for treatment on the human or animal body confers a surgical character on that method, which would bring it within the prohibition of Article 52(4) EPC.

5.9 In the case of a method involving administration of two or more substances, the question for the purposes of Article 52(4) EPC is not whether the main or even the only reason for carrying out the whole of the claimed method is non-therapeutic. Rather a method claim falls under the prohibition of Article 52(4) EPC already if the administration of one of the substances is a treatment by therapy, and the administration of this substance is a feature of the claim.

5.10 The board considers that since the method for preventing pregnancy according to claims 8 to 13 of the main request includes a treatment by therapy the said claims fall within the prohibition on patentability set out in Article 52(4) EPC.

5.11 Given this conclusion, there is no need to go further into the question whether, and if so, in what circumstances a patent can be granted under the European Patent Convention for a method of contraception.

6. First auxiliary request: claims 8 to 14

Claim 8 is directed to the use of an LHRH composition, an oestrogenic steroid and a progestational steroid in the preparation of an agent for preventing pregnancy in a female mammal, the said agent comprising a first and a second delivery system as set out in claim 1. The claim is permissible according to decision G 5/83 (loc.cit.). This claim 8 and, consequently, claims 9 to 14 dependent on it, are considered patentable under the provisions of Article 52(1) EPC for the reasons already given in point 4 above. Thus, the first auxiliary request is allowable.

Order

For these reasons it is decided that:

1. The decision under appeal is set aside.

2. The case is remitted to the first instance with the order that a patent be granted on the basis of the claims of the first auxiliary request submitted during the oral proceedings on 11 January 1994 and a description composed of pages 1 to 5, 7 to 10 and 12 to 16 as originally filed and pages 6 and 11 as filed with the letter of 14 October 1991.

Previous
Next
Footer - Service & support
  • Service & support
    • FAQ
    • Publications
    • Procedural communications
    • Contact us
    • Subscription centre
    • Official holidays
    • Forums
    • Glossary
Footer - More links
  • Jobs & careers
  • Press centre
  • Single Access Portal
  • Procurement
  • Boards of Appeal
SoMe facebook 0
European Patent Office
EPO Jobs
SoMe instagram
EuropeanPatentOffice
SoMe linkedIn
European Patent Office
EPO Jobs
EPO Procurement
SoMe twitter
EPOorg
EPOjobs
SoMe youtube
TheEPO
Footer
  • Legal notice
  • Terms of use
  • Data protection and privacy
  • Accessibility